In the context of its impact on muscular endurance capacity, which is its primary use case in an exercise performance context, Taurine appears to improve the efficiency of ATP turnover in the muscle cell via antioxidant driven stabilizing effects in the mitochondrial matrix [R]
Una fortaleza de nuestro estudio comparado con el de Aoun y sus colaboradores es que se consider desde un inicio que los participantes no estuvieran recibiendo tratamiento con hierro, lo cual pudo explicar la mejora observada en estos autores
GLP-1 Market Size: USD 68.65 billion in 2026 | USD 195.01 billion by 2035 | CAGR: 12.3% | Leading Molecule: Semaglutide ( 52.1% revenue share) | Dominant Region: United States ( 62.8% revenue share) GLP-1 Weight Loss Drug Market Highlights: Key Data at a Glance ( 2026 ) GLP-1 Weight Loss Drug Market Size 2026 : USD 68.65 billion , forecast USD 195.01 billion by 2035 at 12.3% CAGR Dominant drug class: Dual GIP/GLP-1 Agonists (tirzepatide) and Injectable GLP-1 RA Monoagonists (semaglutide) with 78.4% combined revenue share Fastest-growing route: Oral GLP-1 formulations at 34.2% CAGR through 2035 driven by injection-free patient access expansion GLP-1 market leaders: Novo Nordisk and Eli Lilly with approximately 87% combined prescription weight management drug revenue share in 2026 Most prescribed weight loss molecule: Semaglutide (Wegovy and Ozempic) with 52.1% global GLP-1 market revenue share in 2026 FDA-approved anti-obesity GLP-1 drugs: Four molecules including semaglutide, tirzepatide, liraglutide, and oral semaglutide as of 2026 Global obesity patient pool: More than 1.1 billion adults with obesity globally
Awada G, Cascone T, van der Heijden MS, Blank CU, Kok M, Chalabi M
Medical Disclaimer: This article is for educational purposes only and should not be construed as medical advice
